病毒——从病原体到疫苗载体。
Viruses - from pathogens to vaccine carriers.
机构信息
University of Pennsylvania Graduate Program, Philadelphia, PA, USA.
出版信息
Curr Opin Virol. 2011 Oct;1(4):241-5. doi: 10.1016/j.coviro.2011.07.009.
Abstract
Vaccination is mankind's greatest public health success story. By now vaccines to many of the viruses that once caused fatal childhood diseases are routinely used throughout the world. Traditional methods of vaccine development through inactivation or attenuation of viruses have failed for some of the most deadly human pathogens, necessitating new approaches. Genetic modification of viruses not only allows for their attenuation but also for incorporation of sequences from other viruses, turning one pathogen into a vaccine carrier for another. Recombinant viruses have pros and cons as vaccine carriers, as discussed below using vectors based on adenovirus, herpesvirus, flavivirus, and rhabdovirus as examples.
摘要
疫苗接种是人类最伟大的公共卫生成就之一。如今，针对许多曾经导致致命儿童疾病的病毒的疫苗已在全球范围内常规使用。对于一些最致命的人类病原体，通过使病毒失活或减毒来开发疫苗的传统方法已经失败，因此需要新的方法。对病毒进行遗传修饰不仅可以使其减毒，还可以将来自其他病毒的序列整合进去，从而使一种病原体成为另一种病原体的疫苗载体。下面将使用基于腺病毒、疱疹病毒、黄病毒和弹状病毒的载体为例，讨论重组病毒作为疫苗载体的优缺点。
相似文献
1
Viruses - from pathogens to vaccine carriers.病毒——从病原体到疫苗载体。
Curr Opin Virol. 2011 Oct;1(4):241-5. doi: 10.1016/j.coviro.2011.07.009.
2
A focus on vaccination strategies.关注疫苗接种策略。
Viral Immunol. 2014 Nov;27(9):421. doi: 10.1089/vim.2014.1506.
3
Recombinant viruses as vaccines against viral diseases.作为抗病毒性疾病疫苗的重组病毒。
Braz J Med Biol Res. 2005 Apr;38(4):509-22. doi: 10.1590/s0100-879x2005000400004. Epub 2005 Apr 13.
4
Novel viral vectors in infectious diseases.传染病中的新型病毒载体
Immunology. 2018 Jan;153(1):1-9. doi: 10.1111/imm.12829. Epub 2017 Sep 26.
5
DNA vaccines: developing new strategies to enhance immune responses.DNA疫苗：开发增强免疫反应的新策略。
Immunol Res. 2008;42(1-3):219-32. doi: 10.1007/s12026-008-8076-3.
6
Editorial overview.编辑概述。
Curr Opin Virol. 2011 Oct;1(4):223-5. doi: 10.1016/j.coviro.2011.08.005. Epub 2011 Sep 16.
7
Editorial overview: Preventive and therapeutic vaccines: Vaccination against viral disease - current advances and challenges.编辑概述：预防性和治疗性疫苗：针对病毒性疾病的疫苗接种——当前进展与挑战
Curr Opin Virol. 2017 Apr;23:vi-viii. doi: 10.1016/j.coviro.2017.06.001.
8
Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling.新兴病毒的疫苗和佐剂设计：突变、缺失、片段与信号传导
Bioeng Bugs. 2011 May-Jun;2(3):129-35. doi: 10.4161/bbug.2.3.15367. Epub 2011 May 1.
9
New viral vectors for infectious diseases and cancer.新型病毒载体在传染病和癌症中的应用
Semin Immunol. 2020 Aug;50:101430. doi: 10.1016/j.smim.2020.101430. Epub 2020 Nov 29.
10
Viral vectors as vaccine platforms: deployment in sight.病毒载体作为疫苗平台：部署在望。
Curr Opin Immunol. 2011 Jun;23(3):377-82. doi: 10.1016/j.coi.2011.03.006. Epub 2011 Apr 20.
引用本文的文献
1
Research advances in replication-deficient viral vector vaccines.复制缺陷型病毒载体疫苗的研究进展
Front Vet Sci. 2025 Mar 3;12:1535328. doi: 10.3389/fvets.2025.1535328. eCollection 2025.
2
A Comprehensive Review of Our Understanding and Challenges of Viral Vaccines against Swine Pathogens.病毒性疫苗防治猪病的理解与挑战综述
Viruses. 2024 May 24;16(6):833. doi: 10.3390/v16060833.
3
mRNA-based Vaccines Targeting the T-cell Epitope-rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti-Tumor Immunity in Mice.基于 mRNA 的疫苗针对 Epstein Barr 病毒潜伏蛋白的 T 细胞表位丰富域，在小鼠中引发了强大的抗肿瘤免疫。
Adv Sci (Weinh). 2023 Dec;10(35):e2302116. doi: 10.1002/advs.202302116. Epub 2023 Oct 27.
4
Promises and challenges of mucosal COVID-19 vaccines.黏膜 COVID-19 疫苗的前景与挑战。
Vaccine. 2023 Jun 19;41(27):4042-4049. doi: 10.1016/j.vaccine.2023.04.013. Epub 2023 Apr 10.
5
Relationship between blood clots and COVID-19 vaccines: A literature review.血凝块与新冠疫苗之间的关系：一篇文献综述。
Open Life Sci. 2022 Apr 26;17(1):401-415. doi: 10.1515/biol-2022-0035. eCollection 2022.
6
Inhibiting a dynamic viral protease by targeting a non-catalytic cysteine.靶向非催化半胱氨酸抑制动态病毒蛋白酶。
Cell Chem Biol. 2022 May 19;29(5):785-798.e19. doi: 10.1016/j.chembiol.2022.03.007. Epub 2022 Mar 31.
7
Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction.预防性和治疗性EBV疫苗：主要科学障碍、历史进展及未来方向。
Vaccines (Basel). 2021 Nov 7;9(11):1290. doi: 10.3390/vaccines9111290.
8
The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.爱泼斯坦-巴尔病毒预防性疫苗研发的现状与前景
Front Immunol. 2021 Jun 8;12:677027. doi: 10.3389/fimmu.2021.677027. eCollection 2021.
9
Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.兽医学中的新型疫苗技术：人类医学疫苗的先驱
Front Vet Sci. 2021 Apr 15;8:654289. doi: 10.3389/fvets.2021.654289. eCollection 2021.
10
Recombinant adenovirus expressing vesicular stomatitis virus G proteins induce both humoral and cell-mediated immune responses in mice and goats.表达水疱性口炎病毒 G 蛋白的重组腺病毒在小鼠和山羊中诱导体液和细胞介导的免疫应答。
BMC Vet Res. 2021 Jan 18;17(1):36. doi: 10.1186/s12917-020-02740-6.
本文引用的文献
1
Programming the magnitude and persistence of antibody responses with innate immunity.用先天免疫来编程抗体反应的强度和持久性。
Nature. 2011 Feb 24;470(7335):543-7. doi: 10.1038/nature09737.
2
Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques.基于水疱性口炎病毒的 H5N1 禽流感疫苗可诱导恒河猴产生强效的跨谱系中和抗体。
J Virol. 2011 May;85(9):4602-5. doi: 10.1128/JVI.02491-10. Epub 2011 Feb 16.
3
Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults.季节性疫苗预防社区居住老年人中确诊的流感相关住院的效果。
J Infect Dis. 2011 Feb 15;203(4):500-8. doi: 10.1093/infdis/jiq076. Epub 2011 Jan 10.
4
Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.在非人灵长类动物和人类中，载体 HIV 疫苗诱导的 T 细胞免疫反应的比较。
Vaccine. 2010 Nov 23;28(50):7881-9. doi: 10.1016/j.vaccine.2010.09.079. Epub 2010 Oct 23.
5
Hallmark features of immunosenescence are absent in familial longevity.免疫衰老的标志性特征在家族性长寿中并不存在。
J Immunol. 2010 Oct 15;185(8):4618-24. doi: 10.4049/jimmunol.1001629. Epub 2010 Sep 20.
6
Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.腺病毒载体疫苗：三种腺病毒科病毒载体的比较。
J Virol. 2010 Oct;84(20):10522-32. doi: 10.1128/JVI.00450-10. Epub 2010 Aug 4.
7
CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling.复制缺陷型 5 型腺病毒血清型免疫后 CD8+T 细胞反应依赖于 CD11c+树突状细胞，但它们在 TLR 和核苷酸结合寡聚化结构域样受体信号的要求上存在冗余。
J Immunol. 2010 Aug 1;185(3):1513-21. doi: 10.4049/jimmunol.1000338. Epub 2010 Jul 7.
8
A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.基于水疱性口炎病毒的乙型肝炎病毒疫苗载体可提供单次剂量接种的保护作用。
J Virol. 2010 Aug;84(15):7513-22. doi: 10.1128/JVI.00200-10. Epub 2010 May 26.
9
Vesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication.囊泡性口炎病毒基因组 RNA 在没有病毒复制的情况下在体内持续存在。
J Virol. 2010 Apr;84(7):3280-6. doi: 10.1128/JVI.02052-09. Epub 2009 Dec 23.
10
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.黄热病病毒疫苗可诱导广泛且多功能的人类记忆性 CD8+ T 细胞应答。
J Immunol. 2009 Dec 15;183(12):7919-30. doi: 10.4049/jimmunol.0803903.
Zotero 插件